NCT00407511View on ClinicalTrials.gov

Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Diabetic Peripheral Neuropathic Pain (DPN)Postherpetic Neuralgia (PHN)HIV-related Neuropathic Pain (HIV)Chemotherapy Induced Neuropathic Pain
Interventions
DRUG

Pregabalin

Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).

Trial Locations (11)

27

Pfizer Investigational Site, Lima

1020

Pfizer Investigational Site, Caracas

14080

Pfizer Investigational Site, Mexico City

21100

Pfizer Investigational Site, Mexicali

22010

Pfizer Investigational Site, Tijuana

39670

Pfizer Investigational Site, Acapulco de Juárez

64460

Pfizer Investigational Site, México

97000

Pfizer Investigational Site, Mérida

Unknown

Pfizer Investigational Site, Bogota

Pfizer Investigational Site, Quito

L13

Pfizer Investigational Site, Lima

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00407511 - Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP | Biotech Hunter | Biotech Hunter